Mark Scarupa, MD
Basic profileMark Scarupa is a Rheumatology/Immunology physician affiliated with Institute for Asthma and Allergy. OpenAlex indexes 35 publications with 326 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
42 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year202542 payments$37,261
- Blueprint Medicines CorporationProgram year202532 payments$33,744
- GSKProgram year20257 paymentsResearch$22,842
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
56.3%Anti-IgE54.9%Omalizumab100%Part B, office-administered≥30 patientsHistamine-1 Receptor Antagonist0.6%Azelastine-Fluticasone54%Azelastine Hcl46%Part D≥15 patients+ 2 more classes in this area
Anti-infectives
42.9%Human Immunoglobulin G42.7%Immune globulin100%Part B, office-administered≥16 patientsTetracycline-class Drug0.1%Doxycycline Hyclate100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
0.4%Corticosteroid0.4%Prednisone100%Part D≥30 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Bradykinin Quantification To Diagnose and Monitor Normal-C1 Esterase Inhibitor Angioedema
Journal of Allergy and Clinical Immunology
2026 - Correction to: A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency
Journal of Clinical Immunology
2026 - Ex vivo bradykinin as a functional biomarker for angioedema with normal C1-inhibitor
Journal of Allergy and Clinical Immunology Global
2026 - Bradykinin measurement by liquid chromatography tandem mass spectrometry in subjects with hereditary angioedema enhanced by cold activation
Journal of Allergy and Clinical Immunology Global
2025 - A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency
Journal of Clinical Immunology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Kaliner, MD
Institute for Asthma and Allergy
Martha V. White
Institute for Asthma and Allergy
Huamin Li, MD, PhD
Institute for Asthma and Allergy
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”